BioClinica, Inc. and JLL Partners Announce Early Termination of Hart-Scott-Rodino Act Waiting Period
Published: Feb 22, 2013
NEWTOWN, Pa.--(BUSINESS WIRE)--BioClinica®, Inc. (NASDAQ: BIOC), a leading global provider of clinical trial management solutions, and JLL Partners, Inc., a leading private equity investment firm, today announced that early termination of the waiting period under the Hart-Scott-Rodino Antitrust Improvements Act of 1976, as amended, has been granted in connection with the pending acquisition by BC Acquisition Corp., a wholly-owned subsidiary of BioCore Holdings, Inc., of BioClinica for $7.25 per share in cash. As previously announced, JLL is accomplishing the acquisition of BioClinica through a tender offer, which commenced on February 11, 2013 and is scheduled to expire at 12:00 midnight, New York City time, at the end of Monday, March 11, 2013, unless the tender offer is extended. The tender offer is being conducted on the terms and subject to the conditions described in the Offer to Purchase, dated February 11, 2013, and the related Letter of Transmittal, which have been filed as part of a Tender Offer Statement on Schedule TO with the U.S. Securities and Exchange Commission on February 11, 2013.